Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | KLK1 | P06870 | 1/20 | 0.42 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328261 | 0.84 | KMT2A (0.47) | KLKB1KLK1PPARGLMNATHRB | |
| SCHEMBL15734691 | 0.84 | SRC (0.45) | SRCKLKB1KLK1 | |
| SCHEMBL30795252 | 0.84 | SRC (0.45) | SRCKLKB1KLK1 | |
| SCHEMBL2130723 | 0.82 | SRC (0.45) | SRCKLKB1KLK1LMNAALDH1A1 | |
| SCHEMBL30795190 | 0.82 | SRC (0.45) | SRCKLKB1KLK1LMNAALDH1A1 | |
| SCHEMBL30794521 | 0.80 | SRC (0.44) | SRCKLKB1KLK1LMNATHRB | |
| SCHEMBL2129031 | 0.80 | SRC (0.44) | SRCKLKB1KLK1LMNATHRB | |
| SCHEMBL15733457 | 0.79 | SRC (0.46) | SRCSTAT6LMNATHRBGAA | |
| SCHEMBL30795503 | 0.79 | SRC (0.46) | SRCSTAT6LMNATHRBGAA | |
| SCHEMBL19721583 | 0.79 | SRC (0.42) | SRCLMNATHRBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | claimed |
| EP-2844645-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-03-11 | — | — | EP | claimed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | claimed |
| WO-2013156155-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-10-24 | — | — | WO | claimed |
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| EP-2844645-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013156155-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | KCNJ2, KCNQ2, KCNQ1 | SRC 3240/4885KLKB1 1222/4885KLK1 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.